TY - JOUR
T1 - Partial remission and early stages of pediatric type 1 diabetes display immunoregulatory changes. A pilot study
AU - Villalba, Adrian
AU - Fonolleda, Mireia
AU - Murillo, Marta
AU - Rodriguez-Fernandez, Silvia
AU - Ampudia, Rosa Maria
AU - Perna-Barrull, David
AU - Raina, Maria Belen
AU - Quirant-Sanchez, Bibiana
AU - Planas, Raquel
AU - Teniente-Serra, Aina
AU - Bel, Joan
AU - Vives-Pi, Marta
PY - 2019/8/1
Y1 - 2019/8/1
N2 - © 2019 The Author(s) Type 1 diabetes (T1D) is a chronic metabolic disease of unknown etiology that results from β-cell destruction. The onset of the disease, which arises after a long asymptomatic period of autoimmune attack, may be followed by a relapsing and remitting progression, a phenomenon that is most evident during the partial remission phase (PR). This stage lasts for a few months, shows minor requirements of exogenous insulin and could be explained by a recovery of immunological tolerance. This study aims to identify new biomarkers at early stages of pediatric T1D that reflect immunoregulatory changes. To that end, pediatric patients with T1D (n = 52) and age-related control subjects (n = 30) were recruited. Immune response-related molecules and lymphocyte subsets were determined starting at T1D onset and until the second year of progression. Results showed that circulating TGF-β levels decreased during PR, and that betatrophin concentration was increased in all the considered stages without differing among studied checkpoints. Moreover, an increase of regulatory T, B and NK subsets was found during T1D progression, probably reflecting an attempt to restore self-tolerance. By contrast, a reduction in monocyte levels was observed at the early stages of diabetes. The results reveal significant changes in immunological parameters during the different early stages of T1D in children, which could ultimately serve as potential biomarkers to characterize the progression of T1D.
AB - © 2019 The Author(s) Type 1 diabetes (T1D) is a chronic metabolic disease of unknown etiology that results from β-cell destruction. The onset of the disease, which arises after a long asymptomatic period of autoimmune attack, may be followed by a relapsing and remitting progression, a phenomenon that is most evident during the partial remission phase (PR). This stage lasts for a few months, shows minor requirements of exogenous insulin and could be explained by a recovery of immunological tolerance. This study aims to identify new biomarkers at early stages of pediatric T1D that reflect immunoregulatory changes. To that end, pediatric patients with T1D (n = 52) and age-related control subjects (n = 30) were recruited. Immune response-related molecules and lymphocyte subsets were determined starting at T1D onset and until the second year of progression. Results showed that circulating TGF-β levels decreased during PR, and that betatrophin concentration was increased in all the considered stages without differing among studied checkpoints. Moreover, an increase of regulatory T, B and NK subsets was found during T1D progression, probably reflecting an attempt to restore self-tolerance. By contrast, a reduction in monocyte levels was observed at the early stages of diabetes. The results reveal significant changes in immunological parameters during the different early stages of T1D in children, which could ultimately serve as potential biomarkers to characterize the progression of T1D.
KW - Angiopoietin-like Proteins/blood
KW - Biomarkers/blood
KW - Body Mass Index
KW - Case-Control Studies
KW - Child
KW - Diabetes Mellitus, Type 1/blood
KW - Disease Progression
KW - Female
KW - Humans
KW - Immunologic Memory
KW - Lymphocyte Subsets/metabolism
KW - Male
KW - Monocytes/metabolism
KW - Peptide Hormones/blood
KW - Pilot Projects
KW - Remission Induction
KW - Transforming Growth Factor beta/blood
UR - http://www.mendeley.com/research/partial-remission-early-stages-pediatric-type-1-diabetes-display-immunoregulatory-changes-pilot-stud
U2 - 10.1016/j.trsl.2019.03.002
DO - 10.1016/j.trsl.2019.03.002
M3 - Article
C2 - 30953609
SN - 1931-5244
VL - 210
SP - 8
EP - 25
JO - Translational Research
JF - Translational Research
ER -